#Rapt therapeutics stock forecast for free#

was incorporated in 2015 and is headquartered in South San Francisco, California. and changed its name to RAPT Therapeutics, Inc. RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -1.61 and -39.02, respectively, for the quarter ended June 2021. The company was formerly known as FLX Bio, Inc. RAPT Therapeutics EPS misses by 0.01, beats on revenue. This is a 5 percent decrease over losses of (0.60) per share from the same period last year. Adc Therapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. As of 2022 January 01, Saturday current price of ADCT stock is 20.820 and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of (0.63) per share. About the ADC Therapeutics SA stock forecast. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

#Rapt therapeutics stock forecast for free#

Subscribe for free and invest smarter today. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. Find the latest Sarepta Therapeutics (NasdaqGS:SRPT) stock price, news, analyst forecasts, insider trading data, and more. The 5 analysts offering 12-month price forecasts for Kintara Therapeutics Inc have a median target of 5.00, with a high estimate. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.